← All trials
NCT03981523
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Aug 30, 2020
- Completion date
- Aug 30, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 450
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas, El PasoLead sponsor
- University of Texas, El PasoOverall official - principal investigator
- Drugs for Neglected Diseases InitiativeCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of BarcelonaCollaborator
- University of BarcelonaOverall official - principal investigator
- Food and Drug AdministrationCollaborator
- University of Texas, El PasoReponsible party - principal investigator
- Mundo Sano FoundationCollaborator
- Institute of Parasitology and Biomedicine Lopez NeyraCollaborator
- Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)Collaborator
- Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.